Yes. The only way this might be a hell of a play is if the FDA accepts the secondary end points as the criteria for the registration trial---just like TNXP for fibromyalgia. Other than that, it's toast.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.